ERBB2 and breast cancer: This research will provide data on “canonical” treatment outcomes, which may be more appropriately interpreted in light of the results from the annexed tasks and experimental designs focused on the underlying mechanisms regulating the development of resistance across the different subtypes of HER2‐positive metastatic BC patients.